• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Zachary Day, Research Assistant 2, Exploration in Marketing Communications

Zachary Day, Research Assistant 2, Exploration in Marketing Communications

https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/zachary-day-research-assistant-2-exploration-in-marketing-communications/

Assignment #4

Article Information

Article Name
Live Link
Views
All Time
Categories of Research









Interaction of enzymes and hormones








5,179
Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Metabolomics, Population Health Management, Genetics & Pharmaceutical, Population Health Management, Nutrition and Phytochemistry, Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics | Tagged active compounds, enzyme, hormone, interaction, Metabolism, Therapy






Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)






13,894


Coagulation Therapy and Internal Bleeding, Electrophysiology, FDA Regulatory Affairs, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease | Tagged Academic Medical Center, Amsterdam, Anticoagulant, Apixaban, Dabigatran, Direct thrombin inhibitor, Direct Xa inhibitor, Food and Drug Administration, New England Journal of Medicine, Non-steroidal anti-inflammatory drug, Northeastern University, PRADAXA, Prothrombin time, Rivaroxaban, VTE, Warfarin







Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications


8,373
Coagulation Therapy and Internal Bleeding, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease | Tagged Dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation

Corresponding Word Clouds

UPDATED on July 1, 2020

The FIRST Project ZACH will work with AVIVA is on

Project #1:

On Wikipedia creation of 2 entries. Please made you and Aviva the two Curators of the two Entries

  • BEST if they are DRAFT: that I can review and edit before they go LIVE

We will start with Entry 1:

Entry 1

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Step 1: Please CREATE an MS Word NEW File Name it Wikipedia-LPBI

We are adding CONTENT of the following TWO LINKS:

Step 2:

  • Copy and Paste to Wikipedia-LPBI file Content From the FIRST LINK:

1.0 LPBI Executive Summary

Step 3:

  • Copy and Paste to Wikipedia-LPBI file Content From the Second LINK:

2.0 LPBI – 2021-2025 VISION

Step 4:

  • REMOVE from the TEXT ADDED in Step 3 identical content that ALREADY exists in Text of Step 2

Step 5: Spell check

Step 6: Send Wikipedia-LPBI file as attachment in e-mail to AVIVA for Review

Step 7: REFERENCES – will be provided to you

Step 8: The VERSION we accept as final – ZACK will UPLOAD to Wikipedia for the NEW Entry under the Name

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

WE WILL ZOOM to DISCUSS

Entry 2:

Aviva Lev-Ari, PhD, RN 

Step 1: Please CREATE an MS Word NEW File Name it Wikipedia-Aviva

We are adding CONTENT of the following TWO LINKS:

Step 2:

  • Copy and Paste to Wikipedia-Aviva file Content From the FIRST LINK:

Founder’s Bio

Step 3:

  • Copy and Paste to Wikipedia-Aviva file Content From the Second LINK:

Aviva Lev-Ari, PhD, RN, Director and Founder

Step 4:

  • REMOVE from the TEXT ADDED in Step 3 identical content that ALREADY exists in Text of Step 2

Step 5: Spell check

Step 6: Send Wikipedia-Aviva file as attachment in e-mail to AVIVA for Review

Step 7: REFERENCES – will be provided to you

Step 8: The VERSION we accept as final – ZACK will UPLOAD to Wikipedia for the NEW Entry under the Name

Aviva Lev-Ari, PhD, RN 

WE WILL ZOOM to DISCUSS

UPDATED on July 15, 2020

The Second Project ZACH will work with AVIVA is on

Project #2:

Connecting LPBI’s Journal articles to Social Media Icons:

1. Twitter

2. Facebook LPBI Page

3 LinkedIn – Aviva’s Groups

MORE INSTRUCTIONS WILL BE WRITTEN HERE before July 15, 2020

On 6/29/20, 7:38 AM, “Aviva Lev-Ari” <aviva.lev-ari@comcast.net> wrote:

E-mail me WHEN you are ready to Zoom, I will send you an invite.

1. THIS IS A 40 hours a week INTERNSHIP

2. You are part of a GROUP of 5 Interns

3. You will BENEFIT from 1 and 2, above

4. You do not write code in Peyton, the other 4 Interns do.

5. You will benefit from attending TUESDAY sessions on 11AM EST every week, June 26 to August 11, 2020.

6. All coding assignment ARE NOT FOR YOU

7. You need to work 40 hours a week with LPBI.

8. Except for attending The TUESDAYS sessions with each week a PRESENTER, as detailed on the Portal, ZACH is Research Assistant to Aviva

9. On our first Zoom – I will explain the Two Projects you will work with me on

9.1 Wikipedia creation of 2 entries

9.1.1 LPBI per content given to you

9.1.2 Aviva Lev-Ari, PhD, RN entry

9.2 Connecting LPBI’s Journal articles to Social Media Icons:

9.2.1 Twitter,

9.2.2 Facebook Public,

9.2.3 LinkedIn – Aviva’s Groups

To Accomplish 9.1 and 9.2 we need to Zoom.

E-mail me when we can do they today.

Thank you, waiting for your e-mail

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


Loading Comments...
%d